Entry Detail



General Information

Database ID:exR0090789
RNA Name:hsa-miR-299-3p
RNA Type:miRNA
Chromosome:chr14
Starnd:+
Coordinate:
Start Site(bp):101023832End Site(bp):101023853
External Links:hsa-miR-299-3p



Disease Information

Disease Name:Preterm Birth
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D047928
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Premature Birth//Birth, Premature//Births, Premature//Premature Births//Preterm Birth//Birth, Preterm//Births, Preterm//Preterm Births



Expression Detail

GEO ID:GSE106224
Description:Exosomal RNA may reflect placenta deficiencies and provide better biomarker in preterm birth
Experimental Design:Disease vs Control
Case Disease Type:Preterm Birth
Case Disease SubType:NA
Case Sample:Preterm Birth
Control Sample:Control
Number of Case:20
Number of Control:50
Number of Samples:70





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AFF4
chr5
132875395
132963634
-
AK2
chr1
33007940
33080996
-
AP3M1
chr10
74120255
74151063
-
ARCN1
chr11
118572390
118603033
+
CASP2
chr7
143288215
143307696
+
CMIP
chr16
81445170
81711762
+
COL4A2
chr13
110305812
110513209
+
CORO2B
chr15
68578993
68727806
+
DHX33
chr17
5440917
5468982
-
DNAJC9
chr10
73183362
73247255
-
E2F6
chr2
11444375
11466177
-
FHL2
chr2
105357712
105438513
-
GLCCI1
chr7
7968796
8094272
+
LY6E
chr8
143017982
143023832
+
MAP3K14
chr17
45263119
45317029
-
MAP3K2
chr2
127298730
127388465
-
MAP3K20
chr2
173075435
173268015
+
MBNL1
chr3
152243828
152465780
+
MPZL1
chr1
167721192
167791919
+
PCGF3
chr4
705748
770640
+
PGK1
chrX
77910739
78129295
+
PTPRJ
chr11
47980558
48170841
+
RAB8A
chr19
16111889
16134234
+
SAMD4B
chr19
39342396
39385710
+
SORBS3
chr8
22544986
22575788
+
TCF3
chr19
1609290
1652615
-
TMEM127
chr2
96248516
96265994
-
USP37
chr2
218450251
218568351
-
ZIC1
chr3
147393422
147510293
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001349
chr3
152132729
152150709
+
hsa_circ_0001605
chr6
42903447
42905047
+
hsa_circ_0001146
chr20
34241449
34246936
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC016876.2
chr17
7581964
7584086
-
AC135048.1
chr16
30948386
30956511
+
DSCAM-AS1
chr21
40383083
40385358
+
KCNQ1OT1
chr11
2608328
2699994
-
NEAT1
chr11
65422774
65445540
+
TUG1
chr22
30969245
30979395
+
Display:



Experiment Detail

GEO ID:GSE106224
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL18573
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1522
Sample treatment protocol:Whole blood samples were centrifuged for 15 minutes at 2,000×g at 4°C to get plasma. EVs were isolated from 100 ul of plasma using size exclusion columns (iZON qEV, Cambridge MA) with de-gassed 1X PBS from a total of 22 selected samples, 11 from each group (Table 1). Eluate (~500 ul for each fraction) was collected in microfuge tubes individually. The protein contains and concentration for each fraction were assessed by protein gel electrophoresis and Bradford assay (BioRad, Hercules, CA).
RNA Extract protocol:RNA was isolated from all plasma samples, the 22 EV samples, and 22 corresponding EV-depleted fractions using miRNeasy Micro Kit (Qiagne, Germantown MD).
RNA library preparation protocol:Small RNA sequencing libraries were generated with a modified small RNAseq protocol (manuscript in preparation) that alleviates most of the adapter-miRNA ligation sequence bias problem.



Reference

PMID:29516617
Title:Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour
Author:Fallen S, Baxter D, Wu X, Kim TK, Shynlova O, Lee MY, Scherler K, Lye S, Hood L, Wang K
Journal:J Cell Mol Med. 2018 May;22(5):2760-2773.
Description:We have used an improved small RNA library construction protocol and a newly developed size exclusion chromatography (SEC)-based EV purification method to gain a comprehensive view of circulating RNA in plasma and its distribution by analysing RNAs in whole plasma and EV-associated and EV-depleted plasma.